We enrolled 60 patients with newly diagnosed non–germinal center B-cell-like DLBCL in this investigator-initiated, single-arm phase II trial of rituximab, lenalidomide, and ibrutinib (RLI) with the ...
United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer The International ...
In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...
Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE(R) FL-1 study evaluating fixed duration EPKINLY(R) (epcoritamab-bysp) in combination with rituximab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results